Immunoglobulin E (IgE) specific for Ulmus americana pollen allergens (sIgE (Ulmus americana))

Immunoglobulin E (IgE) antibodies specific for Ulmus americana (American Elm) pollen epitopes are the primary mediators of Type I hypersensitivity in individuals sensitized to this tree species. These antibodies are produced by B cells following exposure to pollen proteins, most notably the major allergen Ulm a 1, a pectate lyase [WHO/IUIS Allergen Nomenclature]. These specific IgE (sIgE) molecules circulate in the blood and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to American Elm pollen, the allergen cross-links the surface-bound IgE, triggering the immediate release of inflammatory mediators such as histamine, leukotrienes, and cytokines [PubMed: 29370564]. This physiological cascade results in the clinical symptoms of seasonal allergic rhinitis (hay fever), allergic conjunctivitis, and potentially allergic asthma [AAAAI]. Therapeutic strategies include the use of anti-IgE monoclonal antibodies like omalizumab, which sequester free IgE to prevent mast cell activation, and allergen-specific immunotherapy (AIT), which utilizes American Elm extracts to induce long-term immunological tolerance and shift the immune response from a Th2-mediated allergic profile to a regulatory or Th1-mediated profile [PubMed: 31607455].

Other names

American Elm-specific IgEAnti-Ulmus americana IgEIgE anti-Ulm a 1Ulmus americana-specific Immunoglobulin E

Anti-IgE monoclonal antibodies like omalizumab bind to the Fc region of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on effector cells [FDA: Xolair Label]. Allergen-specific immunotherapy (AIT) involves the controlled administration of Ulmus americana pollen extracts to induce immune tolerance, increase protective IgG4 levels, and modulate T-cell responses [PubMed: 31607455].